2013
Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression
Nunes E, Randall P, Hart E, Freeland C, Yohn S, Baqi Y, Müller C, López-Cruz L, Correa M, Salamone J. Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression. Journal Of Neuroscience 2013, 33: 19120-19130. PMID: 24305809, PMCID: PMC3850037, DOI: 10.1523/jneurosci.2730-13.2013.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine A2 Receptor AntagonistsAdrenergic Uptake InhibitorsAnimalsAntidepressive Agents, Second-GenerationBehavior, AnimalBupropionConditioning, OperantDepressionDisease Models, AnimalDopamineDopamine and cAMP-Regulated Phosphoprotein 32EnkephalinsFeeding BehaviorImmunohistochemistryMaleMicrodialysisMotivationNucleus AccumbensProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleySubstance PTetrabenazineVesicular Monoamine Transport ProteinsXanthinesConceptsMotivational symptomsAnimal modelsEffort-related choice behaviorAdenosine A2A antagonist MSX-3Vesicular monoamine transport (VMAT-2) inhibitor tetrabenazineEffort-related motivational effectsEffort-related motivational symptomsAccumbens medium spiny neuronsVMAT-2 inhibitor tetrabenazineD2 DA receptorsDepression-like effectsDose-related decreaseMedium spiny neuronsEffects of tetrabenazineInhibitor tetrabenazineEffort-related choiceEffort-related effectsDA receptorsAntidepressant bupropionChow intakeMSX-3Spiny neuronsMajor depressionExtracellular dopamineFood intakeEffort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task
Nunes E, Randall P, Estrada A, Epling B, Hart E, Lee C, Baqi Y, Müller C, Correa M, Salamone J. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology 2013, 231: 727-736. PMID: 24136220, PMCID: PMC4468782, DOI: 10.1007/s00213-013-3285-4.Peer-Reviewed Original ResearchConceptsPro-inflammatory cytokines interleukinIL-1βMotivational symptomsEffort-related choice behaviorCytokines interleukinLow dosesEffort-related motivational effectsEffort-related motivational symptomsPro-inflammatory cytokinesLoss of appetiteInvolvement of cytokinesAdministration of cytokinesRatio 5 leverSame dose rangeAdenosine A2A antagonistsEffort-related impairmentsCore body temperatureObjectivesThe present experimentsChow intakeMSX-3ResultsIL-1βAvailable chowFood intakeTendency of ratsA2A antagonists
2012
Dopaminergic Modulation of Effort-Related Choice Behavior as Assessed by a Progressive Ratio Chow Feeding Choice Task: Pharmacological Studies and the Role of Individual Differences
Randall P, Pardo M, Nunes E, Cruz L, Vemuri V, Makriyannis A, Baqi Y, Müller C, Correa M, Salamone J. Dopaminergic Modulation of Effort-Related Choice Behavior as Assessed by a Progressive Ratio Chow Feeding Choice Task: Pharmacological Studies and the Role of Individual Differences. PLOS ONE 2012, 7: e47934. PMID: 23110135, PMCID: PMC3478264, DOI: 10.1371/journal.pone.0047934.Peer-Reviewed Original ResearchMeSH Keywords3,3'-DiaminobenzidineAdenosine A2 Receptor AntagonistsAnalysis of VarianceAnimal FeedAnimal Nutritional Physiological PhenomenaAnimalsChoice BehaviorDopamineDopamine and cAMP-Regulated Phosphoprotein 32Dopamine AntagonistsFeeding BehaviorHaloperidolImmunohistochemistryIndividualityMalePiperidinesPyrazolesRatsRats, Sprague-DawleyXanthinesConceptsProgressive ratioLever pressesPrimary food motivationNucleus accumbens coreCB1 inverse agonistsFood-seeking behaviorChow intakeMSX-3DA transmissionDA antagonismDopaminergic modulationDrug treatmentHigh respondersLaboratory chowLow respondersChow consumptionEffort-related processesSignal transduction activityAccumbens coreMesolimbic dopaminePharmacological studiesFood-reinforced tasksInverse agonistBehavioral activationFood motivationThe novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions
Santerre J, Nunes E, Kovner R, Leser C, Randall P, Collins-Praino L, Cruz L, Correa M, Baqi Y, Müller C, Salamone J. The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacology Biochemistry And Behavior 2012, 102: 477-487. PMID: 22705392, DOI: 10.1016/j.pbb.2012.06.009.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine A2 Receptor AntagonistsAnimalsLocomotionMaleModels, AnimalMotivationProdrugsRatsRats, Sprague-DawleyConceptsMSX-3Amino acid ester prodrugsTreatment of depressionDorsal striatal functionDopamine D2 receptorsSame dose rangeNucleus accumbens coreEffort-related choice behaviorConcurrent leverOral tremorD2 antagonistIntraperitoneal administrationActive dosesLocomotor suppressionMotor functionStriatal functionD2 receptorsAnxiogenic effectsMotor impairmentSelective adenosineAnimal modelsMotivational symptomsAccumbens coreAntiparkinsonian profileEster prodrugs
2011
Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists
Randall P, Nunes E, Janniere S, Stopper C, Farrar A, Sager T, Baqi Y, Hockemeyer J, Müller C, Salamone J. Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology 2011, 216: 173-186. PMID: 21347642, PMCID: PMC3522121, DOI: 10.1007/s00213-011-2198-3.Peer-Reviewed Original Research
2009
Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism
Salamone J, Farrar A, Font L, Patel V, Schlar D, Nunes E, Collins L, Sager T. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behavioural Brain Research 2009, 201: 216-222. PMID: 19428636, PMCID: PMC2806666, DOI: 10.1016/j.bbr.2009.02.021.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine A1 Receptor AntagonistsAdenosine A2 Receptor AntagonistsAnalysis of VarianceAnimalsBehavior, AnimalCaffeineCentral Nervous System AgentsChoice BehaviorConditioning, OperantDopamine AntagonistsDopamine D2 Receptor AntagonistsFeeding BehaviorHaloperidolMaleMotivationPurinesRatsRats, Sprague-DawleyReinforcement ScheduleXanthinesConceptsAdenosine antagonist caffeineEffort-related effectsAntagonist DPCPXAntagonist caffeineDopamine D2 antagonismPreferred lab chowEffects of dopamineEffects of haloperidolAbsence of haloperidolRatio 5 scheduleEffort-related choice behaviorStriatal neuronsReceptor antagonistStriatal areasIP injectionD2 antagonismDopamine receptorsLab chowAdenosine A1The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure
Mott A, Nunes E, Collins L, Port R, Sink K, Hockemeyer J, Müller C, Salamone J. The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology 2009, 204: 103. PMID: 19132351, PMCID: PMC2875244, DOI: 10.1007/s00213-008-1441-z.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine A1 Receptor AntagonistsAdenosine A2 Receptor AntagonistsAnimalsBehavior, AnimalChoice BehaviorConditioning, OperantDopamine AntagonistsDose-Response Relationship, DrugDrug InteractionsHaloperidolMaleMaze LearningMotivationNucleus AccumbensPhysical ExertionPsychomotor PerformanceRatsRats, Sprague-DawleyReceptor, Adenosine A1Receptors, Adenosine A2Reinforcement ScheduleXanthinesConceptsEffort-related choiceMSX-3Antagonist haloperidolAdenosine A2A antagonist MSX-3Receptor antagonist MSX-3Adenosine A2A antagonismDA antagonist haloperidolDopamine antagonist haloperidolEffects of haloperidolEffort-related decision makingFood-seeking behaviorA2A antagonismDA transmissionUntreated ratsA1 antagonistD2 receptorsPsychiatric symptomsAdenosine A2APsychomotor slowingA1 antagonismEffort-related processesBrain circuitryFood-reinforced tasksHaloperidolBehavioral activation